Involving Virus Or Bacteriophage Patents (Class 435/5)
  • Patent number: 9891215
    Abstract: The present invention provides compositions and methods directed to an electrode initialization step for the electrochemical treatment of monolayers used in electrochemical detection of target analytes on the surface of a monolayer. Electrode initialization creates a more stable monolayer, and resolves variability within the electrochemical signal detected on the monolayer.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: February 13, 2018
    Assignee: GENMARK DIAGNOSTICS, INC.
    Inventors: Jon Faiz Kayyem, Ken Rusterholz, William Bender, Sean Ford, Claudia C. Argueta
  • Patent number: 9891214
    Abstract: [Problem] To provide a so-called competitive immunological assay method capable of more uniformly immobilizing on a solid phase a substance equivalent to an antigen. [Solution] This immunological assay method measures an analyte substance in a sample by using: an equivalent substance immobilized on the solid phase during the execution of the assay, the equivalent substance being immunologically equivalent to the analyte substance; and a labeled antibody for specifically binding to the substance equivalent to the analyte substance. The assay method is characterized in that the equivalent substance is immobilized on the solid phase using: a bond between the equivalent substance and a carrier substance, the carrier substance being a substance to which the labeled antibody does not bind; and a bond between the carrier substance and a specific binding substance immobilized on the solid phase, the specific binding substance being a substance that binds specifically to the carrier substance.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: February 13, 2018
    Assignee: TOSOH CORPORATION
    Inventors: Yuki Furuta, Koji Shintani
  • Patent number: 9891233
    Abstract: The present disclosure relates to methods for predicting time-to-delivery in pregnant women. The methods include predicting that a pregnant woman will deliver within a predetermined time frame if PAMG-1 is determined to be present at a level above a predetermined detection threshold in a vaginal fluid sample obtained from the pregnant woman. Also provided are methods for determining a patient's risk of preterm labor and/or spontaneous rupture of the chorioamniotic membrane.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: February 13, 2018
    Assignee: N-Dia, Inc.
    Inventors: Anthony Ausiello, Ruben Salinas, Michael Thompson, Daniel J. Mackey, Kaitlyn Nardozzi, Michael Friedman
  • Patent number: 9879329
    Abstract: Methods and techniques to increase the reliability of detecting virus infections, particularly lymphotropism, to eliminate false negative reactions in testing blood for the presence of lymphotropic viruses during enzyme immunoassay (EIA) and polymerase chain reaction (PCR) testing, and to better detect viruses with lymphotropism in biological materials having a concentration of virus particles lower than the sensitivity threshold of existing EIA and PCR methods, thereby making the techniques of the present invention more reliable.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: January 30, 2018
    Inventor: Nariman Gulyamov
  • Patent number: 9879330
    Abstract: The present invention is a diagnostic kit and materials for: 1) the prediction of the long-term response of a chronic hepatitis B virus (HBV) carrier to treatment with nucleoside/nucleotide analog, or their combination; 2) the detection of HBV variants that exhibit reduced reactivity to antibody detection; 3) the detection of HBV variants in the precore/core region that negatively affect the course of liver disease; 4) the identification of the HBV genotype.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: January 30, 2018
    Assignee: VERSITECH LIMITED
    Inventors: Kaimin Chan, Vivian Nap Yee Chan, Ching Lung Lai, Man Fung Yuen
  • Patent number: 9873922
    Abstract: Methods and techniques to increase the reliability of detecting virus infections, particularly lymphotropism, to eliminate false negative reactions in testing blood for the presence of lymphotropic viruses during enzyme immunoassay (EIA) and polymerase chain reaction (PCR) testing, and to better detect viruses with lymphotropism in biological materials having a concentration of virus particles lower than the sensitivity threshold of existing EIA and PCR methods, thereby making the techniques of the present invention more reliable.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: January 23, 2018
    Inventor: Ovik Leonardovich Mkrtchyan
  • Patent number: 9868997
    Abstract: A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected.
    Type: Grant
    Filed: February 12, 2014
    Date of Patent: January 16, 2018
    Assignee: Becton, Dickinson and Company
    Inventors: Chi Chen, Hugh J. Peck, Michael Porter, Gregory A. Richart, Ray A. McMillian
  • Patent number: 9868108
    Abstract: Sorbent comprising a solid support material, the surface of which comprises first residues comprising a binuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N, O, S, and second residues comprising a mononuclear heteroaromatic structure comprising besides carbon atoms at least one of the heteroatoms N, O, S.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: January 16, 2018
    Assignee: instrAction GmbH
    Inventors: Klaus Gottschall, Markus Arendt, Andres Kirschfeld, Christian Meyer, Markus Weis, Martin Welter, Lothar Ziser
  • Patent number: 9868983
    Abstract: Disclosed is a method for detecting nucleic acids by promoting branched DNA complex formation. The target nucleic acid detection signal and sensitivity can be dramatically increased by promoting self assembly of branched DNA between a plurality of amplified DNA targets and a single-chain oligonucleotide probe, by means of the integrated implementation of PCR, thermal denaturation and hybridization in a single reaction mixture.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: January 16, 2018
    Assignee: Sugentech, Inc.
    Inventors: Chi-Bom Chae, Kyung-Tae Kim, Jong Hun Kang
  • Patent number: 9862990
    Abstract: The present invention relates to compositions and methods for the use of enzymes composed of nucleic acid and/or protein enzymes to generate and amplify a signal indicative of the presence of a target. More particularly, the invention relates to compositions comprising nucleic acid structures that serve as partial or complete enzyme substrates and methods for using these structures to facilitate detection of targets.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: January 9, 2018
    Assignee: SPEEDX PTY LTD
    Inventors: Alison Velyian Todd, Evelyn Meiria Linardy, Elisa Mokany, Dina Lonergan
  • Patent number: 9863010
    Abstract: The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Adenovirus nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers. Kits and methods comprise at least one of these oligomers.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: January 9, 2018
    Inventors: Emily Ziegler, Jessica Townsend
  • Patent number: 9862993
    Abstract: In order to decode arbitrary sequence regions for a large number of genes in a large number of cells, it is necessary to fragment the nucleic acids and introduced a sequence, which differs for each the cell, in the respective fragments. However, in conventional constructions for analyzing large numbers of cells, there was the problem that the cleaved fragments of different regions were intermingled before a tag sequence unique to each region could be introduced. The present invention is constructed to also comprise a genetic analysis system, when trapping nucleic acids extracted from a cell in multiple regions on a substrate and synthesizing and fragmenting the complementary DNA strands (cDNA) of the nucleic acids for each individual region, for immediately introducing a tag sequence unique to each of the regions into said fragments.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: January 9, 2018
    Assignee: HITACHI, LTD.
    Inventors: Maiko Tanabe, Hideki Kambara, Masataka Shirai
  • Patent number: 9862984
    Abstract: The present application discloses methods and apparatuses for single molecule drug screening, discovery and validation. These methods and apparatuses allow a user to detect rapidly, using observation of single molecules, whether and how a drug candidate interferes with a target enzyme involved in a particular disease pathway. The methods and apparatuses described herein utilize single molecule manipulation and detection technologies (e.g., optical or magnetic tweezers) to directly detect whether the characteristic dynamics, or “mechanical signature,” of the target enzyme-substrate interaction are substantially altered or modulated by a drug candidate. Furthermore, the methods and apparatuses are useful for analyzing the modulation of the mechanical signature in order to identify potential interference mechanisms of a drug candidate.
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: January 9, 2018
    Assignee: Nanobiosym, Inc.
    Inventor: Anita Goel
  • Patent number: 9862946
    Abstract: Oligonucleotide analogs conjugated to carrier peptides are provided. The disclosed compounds are useful for the treatment of various diseases, for example diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: January 9, 2018
    Assignee: SAREPTA THERAPEUTICS, INC.
    Inventor: Gunnar J. Hanson
  • Patent number: 9863863
    Abstract: The invention relates to a sensor apparatus (100) and a method for detecting clusters with magnetic particles in a sample. The sample is provided in at least one sample chamber (114) of a substantially planar cartridge (110) that is exposed to a modulated magnetic field (Bxz, Byz) generated by a magnetic field generator (190). The sample chamber (114) is illuminated with excitation light (L0), and the resulting output light (Ls) is detected by a light detector (180). The magnetic field (Bxz, Byz) may particularly rotate, inducing a corresponding rotation of clusters which in turn induces a variation of the detection signal (S). According to a preferred embodiment, excitation light (L0) is focused onto blocking spots (173) behind the sample chamber (114), thus shielding the light detector (180) from direct illumination.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: January 9, 2018
    Assignee: KONINKLIJKE PHILIPS N.V.
    Inventors: Johannes Joseph Hubertina Barbara Schleipen, Menno Willem Jose Prins, Andrea Ranzoni
  • Patent number: 9856474
    Abstract: The present invention is directed to methods and compositions for blocking the effect of the intronic inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The target regions include a unique RNA structure and a 6-nucleotide long sequence that is essential for initiating a long distance steric inhibitory interaction. The identified region provides a novel target deep within SMN2 intron 7. Intronic targets are highly desirable as annealing of an ASO to an intron does not interfere with translation and transport of mRNA. The invention also provides opportunity to employ a short antisense oligonucleotide or a small compound against the unique RNA structure responsible of SMN2 exon 7 skipping in SMA.
    Type: Grant
    Filed: January 16, 2014
    Date of Patent: January 2, 2018
    Assignee: Iowa State University Research Foundation, Inc.
    Inventors: Ravindra N. Singh, Natalia N. Singh
  • Patent number: 9856539
    Abstract: The present disclosure provides adeno-associated virus (AAV) virions with altered capsid protein, where the AAV virions exhibit greater infectivity of retinal cells, when administered via intravitreal injection, compared to wild-type AAV. The present disclosure further provides methods of delivering a gene product to a retinal cell in an individual, and methods of treating ocular disease.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: January 2, 2018
    Assignee: The Regents of the University of California
    Inventors: David V. Schaffer, Ryan R. Klimczak, James T. Koerber, John G. Flannery, Deniz Dalkara Mourot, Meike Visel, Leah C. T. Byrne
  • Patent number: 9856446
    Abstract: The present invention is an apparatus for detecting the presence, quantity and identity of one or more microorganisms in a sample and a method for using the same. The apparatus is composed of one or more chambers and a sensing element for sensing microorganisms. In particular embodiments, the sensing element is an array of chemoresponsive dyes deposited on a substrate in a predetermined pattern combination, wherein the combination of the dyes have a distinct and direct spectroscopic, transmission, or reflectance response to distinct analytes produced by the microorganism which is indicative of the presence, quantity and identity of the microorganism.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: January 2, 2018
    Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Kenneth S. Suslick, Matthew J. Placek, William B. McNamara, III, Avijit Sen, James R. Carey, Jennifer B. Wilson, Crystal K. Keso
  • Patent number: 9856534
    Abstract: Provided herein are methods for selecting use of proteasome inhibitors.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: January 2, 2018
    Assignee: Emory University
    Inventor: Leon Bernal-Mizrachi
  • Patent number: 9850311
    Abstract: An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.
    Type: Grant
    Filed: October 31, 2006
    Date of Patent: December 26, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin Gurney, John Lewicki, Sanjeev Satyal, Timothy Hoey
  • Patent number: 9840712
    Abstract: The present disclosure relates to RNA aptamers and uses thereof, in particular, aptamers which specifically bind to CD133 and which demonstrate superior tumor penetration.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: December 12, 2017
    Assignee: DEAKIN UNIVERSITY
    Inventor: Wei Duan
  • Patent number: 9835629
    Abstract: Methods and sets of non-biological reagents (elution reagents, tag isomers, tag reactive groups, crosslinkers) for single or multiplexed capture and gentle elution of biomolecules. Examples are provided using amine- and cysteine-reactive reagents for enrichment of proteins, peptides, and rare peptide modifications.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: December 5, 2017
    Assignee: Pierce Biotechnology, Inc.
    Inventors: John Charles Rogers, Ryan Daniel Bomgarden, Christopher Laurence Etienne, Eric Leigh Hommema
  • Patent number: 9820476
    Abstract: The invention relates generally to genetically modified non-human animals expressing human polypeptides and their methods of use.
    Type: Grant
    Filed: September 6, 2013
    Date of Patent: November 21, 2017
    Assignees: Regeneron Pharmaceuticals, Inc., Yale University, Institute for Research in Biomedicine (IRB)
    Inventors: Richard Flavell, Markus Manz, Anthony Rongvaux, Till Strowig, Tim Willinger, Andrew J. Murphy, Sean Stevens, George Yancopoulos
  • Patent number: 9825207
    Abstract: A light-emitting diode package element includes a substrate, a plurality of light-emitting dies arranged on the substrate, and a second wavelength-conversion layer. Some of the light-emitting dies are covered with first wavelength-conversion layers thereon, respectively. The first wavelength-conversion layers convert into light with a first color temperature. The second wavelength-conversion layer covers the substrate, the light-emitting dies, and the first wavelength-conversion layers, and converts into light with second color temperature different to the light with the first color temperature.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: November 21, 2017
    Assignee: EDISON OPTO CORPORATION
    Inventor: Kuo-Feng Tseng
  • Patent number: 9824181
    Abstract: The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treatment regime. The methods may also be used to evaluate protein and/or metabolite levels that correlate with such clinical conditions. The methods are also of use to ascertain the probability outcome for a patient's particular prognosis.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: November 21, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: John Zachary Sanborn, David Haussler
  • Patent number: 9816149
    Abstract: The present invention relates to a method for differentiating in a subject with HR-HPV between a severe form of HR-HPV infection and a mild form of HR-HPV infection. It further is concerned with a composition comprising a probe oligonucleotide mixture, a device, and a kit for use in conjunction with the method of the invention.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: November 14, 2017
    Assignee: Deutsches Krebsforschungzentrum
    Inventors: Markus Schmitt, Lutz Gissmann, Michael Pawlita, Daniela Hoefler
  • Patent number: 9810701
    Abstract: The present invention relates to a method for detecting at least one direct factor Xa inhibitor in a sample other than citrate plasma, comprising the step of mixing a sample containing a factor Xa inhibitor with a composition containing factor Xa under conditions which allow the factor Xa to release a detectable substance from a chromogenic substrate.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: November 7, 2017
    Assignee: Doasense GmbH
    Inventors: Job Harenberg, Roland Krämer
  • Patent number: 9809845
    Abstract: This disclosure related to methods and reagents for isothermal amplification of nucleic acid molecules. In some embodiments, methods are provided for amplification of a nucleic acid molecule from a biological sample. Additional embodiments include identification of a target nucleic acid molecule in a biological sample using the disclosed amplification methods.
    Type: Grant
    Filed: August 6, 2012
    Date of Patent: November 7, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jothikumar Narayanan, Prithiviraj Jothikumar, Vincent Hill
  • Patent number: 9803253
    Abstract: A method is described for differentiating in a subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on determining the amount of a first gene product and a second gene product in a sample of a subject and calculating a ratio of the amount of the first gene product and the amount of the second gene product. A composition is also described, including an oligonucleotide mixture, and also a kit and a device adapted to carry out the described method.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: October 31, 2017
    Assignee: Deutsches Krebsforschungszentrum
    Inventors: Markus Schmitt, Lutz Gissmann, Michael Pawlita
  • Patent number: 9803251
    Abstract: Disclosed herein are methods of detecting influenza virus in a sample from a subject. In some embodiments, the disclosed methods include contacting a sample with at least one primer 10-40 nucleotides in length wherein the at least one primer is capable of hybridizing to an influenza virus polymerase basic protein 1 (PB1) nucleic acid at least 70% identical to the nucleic acid sequence set forth as any one of SEQ ID NOs: 1-3, amplifying the PB1 nucleic acid or a portion thereof to produce an amplified PB1 nucleic acid, and detecting the amplified PB1 nucleic acid, wherein presence of the amplified PB1 nucleic acid indicates presence of influenza virus in the sample from the subject. In some examples, the primers comprise or consist of the nucleic acid sequence set forth as one of SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 9, or SEQ ID NO: 10.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: October 31, 2017
    Assignee: The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services
    Inventor: Suxiang Tong
  • Patent number: 9797001
    Abstract: Methods for the high-throughput analysis of transgenic events are herein disclosed. The methods use libraries of sheared genomic DNA ligated to specialized adapters and pooled for sequence analysis and comparison to known genomic and insert sequence. The method finds use in detecting characterizing insertion site, transgene integrity, and transgene copy number.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: October 24, 2017
    Assignee: PIONEER HI-BRED INTERNATIONAL, INC.
    Inventors: Mary Beatty, Kevin Hayes, Jenna Hoffman, Haining Lin, Gina Zastrow-Hayes
  • Patent number: 9790561
    Abstract: The invention provides DNA compositions that relate to transgenic insect resistant maize plants. Also provided are assays for detecting the presence of the maize DP-004114-3 event based on the DNA sequence of the recombinant construct inserted into the maize genome and the DNA sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided.
    Type: Grant
    Filed: October 15, 2013
    Date of Patent: October 17, 2017
    Assignees: PIONEER HI-BRED INTERNATIONAL, INC., E I DU PONT DE NEMOURS AND COMPANY
    Inventors: Scott Diehn, Albert Lu, Timothy Nowatzki, Douglas Nubel, M. Alejandra Pascual, James C. Register, III, Christopher Jay Scelonge, Joshua K. Young, Cathy Xiaoyan Zhong, Erin L. Crowgey
  • Patent number: 9791407
    Abstract: The present invention relates to a real time identification method of working/functional fluid products including a specified tagging material and an apparatus which is first capturing and then identifying the tagging material using a concentrator and an optical detector, simultaneously transferring the reading to a smart unit and finally releasing the tagging material.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: October 17, 2017
    Assignees: Koc Universitesi, Kuantag Nanoteknolojiler Gelistirme ve Uretim A.S.
    Inventors: Hakan Urey, Havva Yagci Acar, Caglar Elbuken, Basarbatu Can, Osman Vedat Akgun, Fahri Kerem Uygurmen
  • Patent number: 9789175
    Abstract: Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 17, 2017
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: David B. Weiner, Daniel Villarreal
  • Patent number: 9791435
    Abstract: A method for the identification and quantification of the expression of membrane receptors present on the surface of target cells using at least two soluble receptor binding ligands derived from the soluble part of the glycoprotein of an enveloped virus that interacts with a cellular cognate receptor, the receptor binding ligand containing a part or the totality of one of the receptor binding domains (RBD) of the glycoprotein, and the soluble receptor binding ligand being liable to interact with the at least one membrane receptor of a target cell, for the identification and quantification of the expression of membrane receptors present on the surface of target cells, the identification and quantification taking place at a given time or during a given time interval, and allowing the determination of a physiological state of the target cell.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: October 17, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE MONTPELLIER 2
    Inventors: Marc Sitbon, Jean-Luc Battini, Naomi Taylor, Cedric Mongellaz
  • Patent number: 9777044
    Abstract: The present application relates to polypeptides derived from the soluble part of the glycoprotein of the enveloped virus of Primate T-cell leukemia virus (PTLV), or fragments or variants thereof named receptor binding domain ligands (RBD) selected for their ability to bind specifically to the nutrient transporter GLUT1.
    Type: Grant
    Filed: December 18, 2014
    Date of Patent: October 3, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE MONTPELLIER 2
    Inventors: Jean-Luc Battini, Nicolas Manel, Felix Kim, Sandrina Kinet, Naomi Taylor, Marc Sitbon
  • Patent number: 9775835
    Abstract: Disclosed herein are compounds, compositions and methods of their use to treat HIV/AIDS disease in a subject in need thereof, wherein the compositions comprise small molecule inhibitors that inhibit viral preparation or viral recruitment of human tRNA3Lys.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: October 3, 2017
    Assignee: Sirga Advanced Biopharma, Inc.
    Inventors: Franck Vendeix, Paul F. Agris
  • Patent number: 9775918
    Abstract: Disclosed are tyrosine-modified rAAV vectors, as well as infectious virions, compositions, and pharmaceutical formulations that comprise them. Also disclosed are methods of preparing and methods for using the disclosed tyrosine-phosphorylated capsid protein mutant rAAV vectors in a variety of diagnostic and therapeutic applications including in vivo and ex vivo gene therapy, and large-scale production of rAAV vectors.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: October 3, 2017
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Li Zhong, Sergei Zolotukhin, Lakshmanan Govindasamy, Mavis Agbandje-McKenna, Arun Srivastava
  • Patent number: 9771572
    Abstract: Method, composition, kit and system for isolating amplifiable nucleic acid from specimens preserved in a liquid-based cytology preservative that contains formaldehyde. The technique relies on the use of 2-imidazolidone and a protease enzyme, such as proteinase K, at elevated temperatures. Advantageously, RNA can be isolated and used as a template in nucleic acid amplification reactions.
    Type: Grant
    Filed: March 21, 2014
    Date of Patent: September 26, 2017
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Deborah C. Jensen, Brett W. Kirkconnell, Timothy J. Wilson
  • Patent number: 9771571
    Abstract: Method, composition, kit and system for isolating amplifiable nucleic acid from specimens preserved in a liquid-based cytology preservative that contains formaldehyde. The technique relies on the use of 2-imidazolidone and a protease enzyme, such as proteinase K, at elevated temperatures. Advantageously, RNA can be isolated and used as a template in nucleic acid amplification reactions.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: September 26, 2017
    Assignee: GEN-PROBE INCORPORATED
    Inventors: Deborah Christine Jensen, Brett Wolfe Kirkconnell, Timothy Joseph Wilson
  • Patent number: 9771400
    Abstract: A natural protein, specifically silk fibroin or sericin, is chemically modified such that it can be rendered photoactive, but which otherwise has similar structure and attributes as silk fibroin or sericin. This chemically modified silk conjugate can be patterned using radiant energy to produce patterned silk materials which may be used for a wide variety of applications such as making micro and nanoparticles of different shapes and functionalities for drug delivery, creating new forms of intricate 3D scaffolds for tissue engineering, and forming substrates for flexible bio-electronics.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: September 26, 2017
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: Nicholas E. Kurland, Vamsi K. Yadavalli
  • Patent number: 9772332
    Abstract: This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having an amino acid sequence shown in any even-numbered SEQ ID NO shown in SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a therapeutic drug targeting CAPRIN-1 to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: September 26, 2017
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takayoshi Ido, Fumiyoshi Okano
  • Patent number: 9765309
    Abstract: Presented herein are polymerase enzymes for improved incorporation of nucleotide analogs, in particular nucleotides which are modified at the 3? sugar hydroxyl, as well as methods and kits using the same.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: September 19, 2017
    Assignee: ILLUMINA, INC.
    Inventors: Cheng-Yao Chen, Erin Bomati, Molly He
  • Patent number: 9765115
    Abstract: The chain of events that explains calcitonin receptor (CTR)-stimulated invasion and metastasis of prostate cancer cells was identified. The CTR-stimulated events depend on the interaction of CTR with the PDZ3 domain of ZO-1. Small peptides and small molecules were identified that inhibit this interaction. The small inhibitory peptides were synthesized and can be used to attenuate or inhibit metastasis in solid cancer tumors.
    Type: Grant
    Filed: March 30, 2012
    Date of Patent: September 19, 2017
    Assignee: Board of Supervisors of Louisiana State University acting on behalf of the University of Louisiana at Monroe
    Inventor: Girish V. Shah
  • Patent number: 9765155
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: September 19, 2017
    Assignee: City of Hope
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9764023
    Abstract: The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: September 19, 2017
    Assignee: Academish Ziekenhuis Leiden H.O.D.N. LUMC
    Inventors: Sjoerd Henricus Van Der Burg, Gemma G. Kenter, Cornelis Johannes Melief
  • Patent number: 9758818
    Abstract: Disclosed herein is a polymerase chain reaction (PCR)-based method for detecting an insertion/deletion variant, as compared with a reference sequence, in a selected region of a target gene in a sample. The target gene has a template strand and a coding strand complementary to the template strand. The method uses a primer set that includes a blocking primer, and a forward primer. The blocking primer and the forward primer are partially overlapping and have different melting temperatures, and the 3?-end of the blocking primer is modified to prevent the extension of the blocking primer during the PCR. Accordingly, under specific PCR conditions, the presence of the PCR product is indicative of the presence of an insertion/deletion mutation in the selected region, and the absence of the PCR product is indicative of the absence of an insertion/deletion mutation in the selected region.
    Type: Grant
    Filed: December 30, 2011
    Date of Patent: September 12, 2017
    Inventors: Jr-Kai Huang, Chi-Kuan Chen, Tao-Yeuan Wang
  • Patent number: 9753038
    Abstract: This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against CAPRIN-1 having the amino acid sequence shown in any even-numbered SEQ ID NO of SEQ ID NOs: 2 to 30 in the Sequence Listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of CAPRIN-1 in a sample of a cancer patient in order to determine the administration of a CAPRIN-1-targeting drug to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-CAPRIN-1 antibody.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: September 5, 2017
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Takayoshi Ido, Fumiyoshi Okano
  • Patent number: 9753034
    Abstract: A process for the identification of compounds with a molecular weight in the range 100 to 750 which inhibit the binding of the first and/or second bromodomains of human BRD-2 to 4 to acetylated lysine residues of their physiological partner proteins which comprises selecting those compounds which are able to: a) form a hydrogen bonding interaction in which the compound accepts a hydrogen bond from the sidechain NH2 group of the asparagine residue found at: BRD-2 BRD-2 BRD-3 BRD-3 BRD-4 BRD-4 BD1 BD2 BD1 BD2 BD1 BD2 ASN156 ASN429 ASN116 ASN391 ASN140 ASN433 or b) accept a water-mediated hydrogen bond in which the compound accepts a hydrogen bond from a water that is itself hydrogen-bonded to the sidechain hydroxyl of the tyrosine residue found at BRD-2 BRD-2 BRD-3 BRD-3 BRD-4 BRD-4 BD1 BD2 BD1 BD2 BD1 BD2 TYR113 TYR386 TYR73 TYR348 TYR97 TYR390 and c) which are also able to form a Van der Waals interaction with a lipophi
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: September 5, 2017
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Paul Bamborough, Chun-Wa Chung
  • Patent number: 9751913
    Abstract: A genetically modified cowpea mosaic virus (CPMV) protein capsid serves as a scaffold for metal nanoparticles, preferably gold nanospheres, of 15 nm to 35 nm, creating plasmonic nanoclusters. The self-assembled nanoclusters gave rise to a 10-fold surface-averaged enhancement of the local electromagnetic field. Other viral capsids or virus-like proteins may also serve as such scaffolds.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: September 5, 2017
    Assignee: The United States of America, as represented by the Secretary of the Navy
    Inventors: Banahalli R. Ratna, Carissa M. Soto, Ronald W. Rendell, Jake Fontana, Jeffrey R. Deschamps